脂肪性肝炎
益生元
抗性淀粉
医学
疾病
肝病
随机对照试验
人口
脂肪肝
内科学
慢性肝病
临床试验
生物信息学
胃肠病学
生物
淀粉
生物化学
环境卫生
肝硬化
作者
Xiang Zhang,Jun Yu,Vincent Wai‐Sun Wong
标识
DOI:10.1016/j.cmet.2023.07.004
摘要
Metabolic dysfunction-associated steatotic liver disease is a prevalent chronic liver disease that affects nearly a third of the global adult population. Here, we preview a randomized controlled clinical trial on the potential benefits and underlying mechanisms of using resistant starch, a prebiotic, for treating this common liver condition.
科研通智能强力驱动
Strongly Powered by AbleSci AI